Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year ...

New treatment advances are providing a lot of hope, and even a potential cure, for difficult to treat large B-cell lymphoma ...

The presence of prostate cancer may be indicated by symptoms, physical examination, prostate-specific antigen (PSA), or ... Many low-risk tumors can be safely followed with active surveillance.

Apr. 11, 2025 — A multi-institutional team developed a chimeric antigen receptor (CAR ... role in the progression of cancer: it shapes the properties of tumor cells and drives the development ...

THIS YEAR the Spanish capital, Madrid, provided the backdrop for Europe’s biggest urological event, the 40th Annual European ...

In a preclinical study, Cedars-Sinai investigators have demonstrated how age-related changes to cells surrounding a tumor ...

LUT014, a BRAF inhibitor gel, improved acne-like rashes in patients with colorectal cancer undergoing anti-EGFR therapy, ...

Apr. 9, 2025 — A small protein involved in neurodegeneration leading to Parkinson's disease also drives a type of skin cancer known as melanoma, according to new ... Apr. 2, 2025 — Scientists ...

Patients with primary Merkel cell carcinoma are at an increased risk of developing a secondary skin cancer vs other malignancies.

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients ...